Perceptive Capital Solutions Corp

PCSC

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RA Capital Management RTW Investments

AI Signal

AI analyst context —

Catalysts

No catalysts tracked.

Activist Filings

SC 13DRA Capital Management8.4%Dec 12, 2025

SC 13GRA Capital Management8.4%Jun 24, 2024

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 750,000Value: $9.8M

# Signal Note: RA Capital initiates PCSC position RA Capital's $9.8M entry into Perceptive's SPAC (PCSC) signals conviction in an unnamed biotech merger target, likely in early-to-mid stage development given the crossover fund's typical thesis. Without disclosed merger details, the position's significance depends on the acquisition target's clinical stage, mechanism novelty, and unmet medical need—expected to materialize in coming weeks as SPAC merger announcement typically precedes close by 60-90 days.

RTW InvestmentsNEW

More PCSC Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TSHA2 funds EVMN2 funds CAPR2 funds FDMT2 funds JBIO2 funds GHRS2 funds SYRE2 funds WVE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RTW Investments Initiates PCSC Position RTW Investments' $9.7M entry into PCSC warrants attention given Wong's selective, thesis-driven approach to biotech allocations. PCSC is a blank-check vehicle; the signal's relevance depends on the pending SPAC merger target—currently unclear from public filings. Monitor SEC filings for merger announcement details, as the meaningful catalyst will be the disclosed company's pipeline stage, clinical data readouts, and cash runway rather than the SPAC structure itself.